- Conditions
- Prostate Cancer
- Interventions
- IMC-A12, Bicalutamide, Goserelin
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 3
- States / cities
- Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 431
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Infertility
- Interventions
- menotropin, recombinant FSH
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 21 Years to 35 Years · Female only
- Enrollment
- 620 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 35
- States / cities
- Scottsdale, Arizona • Tempe, Arizona • Encino, California + 32 more
- Conditions
- Metastatic Hormone-Sensitive Prostate Cancer
- Interventions
- Pembrolizumab, Enzalutamide, Androgen Deprivation Therapy (ADT), Placebo
- Biological · Drug · Other
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 27
- States / cities
- Anchorage, Alaska • Duarte, California • Los Angeles, California + 22 more
- Conditions
- Delayed Puberty, Precocious Puberty
- Interventions
- Leuprolide Acetate - Early Puberty Leuprolide Visit, Ganirelix - Early Puberty Ganirelix Visit, Ganirelix - Delayed Puberty Ganirelix Visit, Leuprolide Acetate- Delayed Puberty Leuprolide Visit
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Primary Amenorrhea With Hypogonadotropic Hypogonadism
- Interventions
- Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump, Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump, Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump, Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 33
- States / cities
- Tempe, Arizona • San Francisco, California • Aurora, Colorado + 28 more
- Conditions
- Menopause, Estrogen Deficiency, Women, Aging
- Interventions
- GnRH antagonist
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer, Prostate Adenocarcinoma
- Interventions
- EPI-7386, Enzalutamide, Androgen Deprivation Therapy (ADT)
- Drug
- Lead sponsor
- Pedro Barata, MD, MSc
- Other
- Eligibility
- 19 Years and older · Male only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio
- Conditions
- Endometriosis, Infertility
- Interventions
- Leuprolide acetate in depot suspension, No intervention
- Drug · Other
- Lead sponsor
- Colorado Center for Reproductive Medicine
- Other
- Eligibility
- 21 Years to 42 Years · Female only
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- Lone Tree, Colorado
- Conditions
- Advanced Breast Cancer
- Interventions
- Lerociclib + Letrozole or Fulvestrant
- Drug
- Lead sponsor
- EQRx, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 6
- States / cities
- Jacksonville, Florida • Omaha, Nebraska • Salem, Oregon + 3 more
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Interventions
- enzalutamide, bicalutamide, orchiectomy, leuprolide acetate, goserelin acetate, laboratory biomarker analysis
- Drug · Procedure · Other
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Detroit, Michigan • Columbus, Ohio
- Conditions
- Healthy Volunteers
- Interventions
- Testosterone, Goserelin acetate
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 60 Years to 75 Years · Male only
- Enrollment
- 177 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Myelodysplastic Syndrome, Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia
- Interventions
- First Allogeneic Bone Marrow Transplant (BMT), Leuprolide, 18F FLT, Cyclophosphamide, Methotrexate, Tacrolimus, Total Body Irradiation, Busulfan, Fludarabine, Second Allogeneic Bone Marrow Transplantation
- Procedure · Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 4 Years to 55 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Bethesda, Maryland • Oklahoma City, Oklahoma
- Conditions
- Breast Cancer
- Interventions
- Anastrozole (Arimidex), Goserelin (Zoladex)
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2013
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Early-stage Breast Cancer, Hypoactive Sexual Desire Disorder, Hormone Receptor Positive Breast Carcinoma, Breast Cancer
- Interventions
- Aromatase Inhibitors, Bupropion, GnRH agonist
- Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Darolutamide
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Prostate Cancer
- Interventions
- Patient Education
- Behavioral
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Androgen Deprivation Therapy, Prostate Cancer, Hypertension, Autonomic Dysfunction, Renal Disease
- Interventions
- Gonadotropin Releasing Hormone Agonists (GNRH), Androgen receptor (AR) inhibitor, Placebo
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 40 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Adenocarcinoma of the Prostate, Prostate Cancer
- Interventions
- Docetaxel, Estramustine, Casodex, Zoladex
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Burlington, Massachusetts • Worcester, Massachusetts + 1 more
- Conditions
- Cognitive Impairment, Executive Dysfunction, Endothelial Dysfunction, Cardiovascular Disease
- Interventions
- Leuprolide acetate, Estradiol, Medroxyprogesterone, Placebo
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 40 Years to 60 Years · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Boulder, Colorado
- Conditions
- Transgenderism, Insulin Sensitivity/Resistance, Endothelial Dysfunction, Vascular Stiffness
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 9 Years to 14 Years · Male only
- Enrollment
- 30 participants
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- Interventions
- Giredestrant, Exemestane, Fulvestrant, Tamoxifen, Everolimus, LHRH Agonist, Dexamethasone Mouth Rinse
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 373 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 55
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 47 more
- Conditions
- Breast Cancer
- Interventions
- Ribociclib
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Boston, Massachusetts
- Conditions
- Fibrolamellar Carcinoma, Fibrolamellar Liver Cancer
- Interventions
- everolimus, letrozole plus leuprolide, combination of everolimus, letrozole and leuprolide
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 6
- States / cities
- San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
- Conditions
- Prostate Cancer, Bone Metastases, Prostate Neoplasms
- Interventions
- LHRH agonist/antagonist, Bicalutamide, Radium-223 dichloride
- Drug · Radiation
- Lead sponsor
- Ajjai Alva, MD
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Peoria, Illinois • Indianapolis, Indiana + 8 more